Delving into the Latest Updates on Mitomycin intravesical(Halozyme Therapeutics, Inc.) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Chemophase, Hyaluronidase-mitomycin, Mitomycin intravesical

+ [2]

Target

DNA

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication-

Inactive Indication

Bladder CancerNon-Muscle Invasive Bladder Neoplasms

Originator Organization

Halozyme Therapeutics, Inc.

Active Organization-

Inactive Organization

Halozyme Therapeutics, Inc.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC15H18N4O5

InChIKeyNWIBSHFKIJFRCO-WUDYKRTCSA-N

CAS Registry50-07-7

The purpose of this research study is to test the safety and tolerability of an experimental drug, Chemophase, a combination of recombinant human hyaluronidase, (an investigational synthetic enzyme also known as rHuPH20), and mitomycin (MMC) in the treatment of superficial bladder cancer when instilled intravesically immediately after TURBT (transurethral resection of bladder tumor).

Start Date01 Oct 2008

Sponsor / Collaborator

Halozyme Therapeutics, Inc.

100 Clinical Results associated with Mitomycin intravesical(Halozyme Therapeutics, Inc.)

Login to view more data

100 Translational Medicine associated with Mitomycin intravesical(Halozyme Therapeutics, Inc.)

Login to view more data

100 Patents (Medical) associated with Mitomycin intravesical(Halozyme Therapeutics, Inc.)

Login to view more data

10

Literatures (Medical) associated with Mitomycin intravesical(Halozyme Therapeutics, Inc.)

01 Jan 2021·International Journal of HyperthermiaQ2 · MEDICINE

Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer

Q2 · MEDICINE

ArticleOA

Author: Lin, Yung-Wei ; Wen, Yu-Ching ; Shih, Hung-Jen ; Fan, Yen-Chun ; Lai, Benjamin Chung Howe ; Lee, Hsin-Lun ; Lee, Liang-Ming ; Lin, Ke-Hsun ; Syu, Syuan-Hao

OBJECTIVESTo compare the therapeutic effects of locoregional deep hyperthermia combined with intravesical chemotherapy with those of intravesical chemotherapy alone in patients with intermediate-/high-risk non-muscle invasive bladder cancer (NMIBC). To evaluate the impact of thermal dose in hyperthermia treatment.METHODSWe analyzed data retrieved from the medical records of patients with intermediate-/high-risk NMIBC treated with intravesical mitomycin (IM group) or locoregional deep hyperthermia combined with intravesical mitomycin (CHT group) at a single tertiary care hospital between May 2016 and June 2019. The primary and secondary endpoints were the recurrence-free survival rate and progression-free survival rate, respectively. Thermal dose was evaluated and adverse events were also recorded.RESULTSIn total, 43 patients (CHT: 18 patients, IM: 25 patients) were enrolled. The median follow-up durations were 14 and 23 months, respectively. The recurrence rate at 12 months was significantly lower in the CHT group than in the IM group (11.1% vs. 44%, p = .048); this trend persisted at 24 months (CHT: 11.1%, IM: 48%; p = .027). The recurrence-free survival was also significantly higher in the CHT group than in the IM group (p = .028). No tumor recurrence was noted in patients who received a thermal dose of ≥4 CEM43. All adverse events were well tolerated, and there was no treatment-related mortality.CONCLUSIONSIntravesical chemotherapy combined with locoregional deep hyperthermia for intermediate-/high-risk papillary NMIBC can significantly decrease the recurrence rate relative to that observed after intravesical chemotherapy alone.

01 Jan 2021·SAGE Open Medical Case Reports

A case of cutaneous necrosis due to intra-articular hyaluronic acid and treated with hyaluronidase

Article

Author: Côté, Benoît ; Qing Huang, Yu ; Costa, Jean-Pascal ; Bouffard, Danielle ; Aaron, Michelle

A 66-year-old woman presented to the hospital with cutaneous necrosis of her right ankle and foot. Her symptoms began immediately after an intra-articular injection of hyaluronic acid for ankle osteoarthritis, which was performed 6 days before. Histopathology showed an intra-vascular hyaluronic acid embolus. The initial treatment approach was conservative, but the patient’s clinical state degraded. She was thus treated with sub-cutaneous hyaluronidase, the enzyme that degrades hyaluronic acid, which yielded a moderate improvement even though it was administered 22 days after the initial hyaluronic acid injection. Although hyaluronic acid embolism and subsequent cutaneous necrosis are well-known complications of dermal fillers, there are few reported cases of embolism following intra-articular injection. To our knowledge, this is the first time hyaluronidase has been used in this setting.

01 Sep 2006·Journal of VoiceQ3 · MEDICINE

Investigation of Anti-Hyaluronidase Treatment on Vocal Fold Wound Healing

Q3 · MEDICINE

Article

Author: Alejandro Munoz-del-Rio ; Xin Hong Lim ; Diane M. Bless ; Bernard Rousseau ; Ichiro Tateya

SUMMARYPhytochemical constituents of medicinal plants demonstrate inhibition of tissue and bacterial hyaluronidase. Echinacoside is a caffeoyl conjugate of Echinacea with known anti-hyaluronidase properties. The purpose of this study was to investigate the wound healing effects of Echinacea on vocal fold wound healing and functional voice outcomes. Pig animal model.METHODSVocal fold injury was induced in 18 pigs by unilateral vocal fold stripping. The uninjured vocal fold served as control. Three groups of six pigs randomly received a topical application of 300, 600, or 1,200 mg of standardized Echinacea on the injured side. Animals were euthanized after 3, 10, and 15 days of wound healing. Phonation threshold pressure and vocal economy measurements were obtained from excised larynges. Treatment outcomes were examined by comparing the animals receiving treatment with a set of 19 untreated and 5 historical controls. Treatment effects on wound healing were evaluated by histologic staining for hyaluronan and collagen. Treated larynges revealed improved vocal economy and phonation threshold pressure compared with untreated larynges. Histologically, treated vocal folds revealed stable hyaluronan content and no significant accumulation of collagen compared with control. Findings provide a favorable outcome of anti-hyaluronidase treatment on acute vocal fold wound healing and functional measures of voice.

100 Deals associated with Mitomycin intravesical(Halozyme Therapeutics, Inc.)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB06205

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Muscle Invasive Bladder Neoplasms	Phase 2	US	Halozyme Therapeutics, Inc.	01 Oct 2008
Bladder Cancer	Phase 2	-	Halozyme Therapeutics, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00318643 (CTgov)	Phase 1/2	Non-Muscle Invasive Bladder Neoplasms	27	Mitomycin C+Chemophase (Cohort 5: MMC Plus Chemophase 800,000 U)	seaktyuciw(fyxnzgxopc) = ejeenfweui hocivcsexp (yuwzyzmdgz, uclucfulya - izanrjujdk) View more	-	29 Oct 2021
NCT00318643 (CTgov)	Phase 1/2	Non-Muscle Invasive Bladder Neoplasms	27	Mitomycin C+Chemophase (Cohort 1: MMC Plus Chemophase 20,000 U)	tawzgdbkgi(ckpwjtchbs) = ebqrgovzof hpokwrfqvl (wpugkbiwwb, eogitjkuul - qhlatlvomq) View more	-	29 Oct 2021
NCT01928030 (CTgov)	Phase 1/2	Neoplasms \| Lymphedema	3	rHuPH20+Chemophase	qbduowpvku(skzipbkjzj) = yxcfmdztla rxmwuyenqd (qpfiidjbhf, zbuvulytyz - qynvjdpupx) View more	-	07 Feb 2017